- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04234516
Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder
Functional Brain Mechanisms Underlying the Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The current opioid epidemic is an urgent public health problem, contributing significantly to the climbing U.S. suicide rates over the past two decades.
Although initially rewarding, chronic opioid use leads to tolerance and escalating negative affective states. This may promote suicidal ideation and may further impair decision-making functions leading to suicidal behavior.
Buprenorphine, a treatment for opioid use disorder (OUD), has promise in reducing suicidal ideation. However, the neural mechanism of its anti-suicidal properties remains unknown. Blocking kappa opioid receptors is one mechanism of buprenorphine hypothesized to reverse the negative emotional sensitivity in OUD and thus may underlie its anti-suicidal effects.
In this morphine-controlled study, we will examine the effect of buprenorphine on the functional activity of brain regions involved in negative emotional reactivity and investigate whether this effect is associated with its anti-suicidal properties.
Buprenorphine has a different mechanism of action than currently available antidepressants and anti-suicidal medications. Understanding this mechanism can help refine its use in this context. Success will guide a future larger study to elucidate molecular mechanisms underlying anti-suicidal properties of buprenorphine.
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- New York State Psychiatric Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-55 years old
- Current opioid use disorder (mild, moderate or severe)
- Seeking treatment for opioid use disorder and willing to accept agonist-based therapy and be stabilized on buprenorphine when study is over
- Active suicidal ideation
- Participant must agree to voluntary admission to New York State Psychiatric Institute (NYSPI) inpatient research unit with confirmed bed availability
- Capacity to provide informed consent
Exclusion Criteria:
- Presence of chronic pain of sufficient severity as to require ongoing pain management with opioids
- Current active psychosis or mania
- Current moderate-severe alcohol, benzodiazepine, or other drug use likely to require a medical detoxification
- Unstable epilepsy or other neurological disorder
- A history of prior head trauma with evidence of cognitive impairment. Participants who endorse a history of prior head trauma will be administered Trail-making A and B test. Those who score 1.5 standard deviations below the mean on Trail- making A or B will be excluded from study participation
- Active significant medical illness that, in the opinion of the study physician, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease)
- Liver Function Tests (ALT, AST) greater than 5 times upper limit of normal
- On methadone-maintenance therapy
- Contraindication to any study treatment (e.g., Known allergy or sensitivity to buprenorphine)
- Pending legal action or other reasons that might prevent an individual from completing the study
- If female, currently pregnant or breastfeeding, or planning on conception
- Inadequate understanding of English
- Metal implants or paramagnetic objects contained within the body (including heart pacemaker, shrapnel, or surgical prostheses) which may present a risk to the subject or interfere with the MRI scan
- Claustrophobia significant enough to interfere with MRI scanning
- Weight over 350 lbs or inability to fit into MRI scanner
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Buprenorphine
Sublingual buprenorphine-naloxone films
|
3 x 8 mg sublingual buprenorphine/naloxone films wrapped inside one Listerine strip at 8 pm daily + oral placebo pills q.i.d.
Other Names:
|
Active Comparator: Morphine
Oral morphine sulphate tablets
|
oral morphine sulphate 30 mg immediate release tablets q.i.d.
+ two sublingual Listerine strips at 8 pm
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Beck Scale for Suicidal Ideation (SSI) scores from baseline to Week 2 post-treatment
Time Frame: 2 weeks
|
Clinician-based questionnaire measuring level of suicidal ideas over the last 7 days; 21 items scored 0 to 2; total score ranges from 0 to 38 (last 2 items not counted), higher scores mean more intense suicidal ideas.
|
2 weeks
|
Changes in functional magnetic resonance imaging (fMRI) blood oxygen-level dependent (BOLD) signal in the amygdala in response to negative vs. neutral pictures from baseline to Week 2 post-treatment
Time Frame: 2 weeks
|
fMRI negative picture task administered at baseline and week 2 post-treatment
|
2 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Mina M Rizk, MD, Columbia University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Chemically-Induced Disorders
- Self-Injurious Behavior
- Narcotic-Related Disorders
- Suicide
- Substance-Related Disorders
- Suicidal Ideation
- Opioid-Related Disorders
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Narcotic Antagonists
- Buprenorphine
- Naloxone
- Buprenorphine, Naloxone Drug Combination
- Morphine
Other Study ID Numbers
- IRB #7855
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Suicidal Ideation
-
University of WashingtonUnited States Department of Defense; Military Suicide Research ConsortiumCompletedSuicidal and Self-injurious Behavior | Suicidal Ideation ActiveUnited States
-
The Catholic University of AmericaUniversity of Washington; VA Office of Research and DevelopmentCompletedSuicidal and Self-injurious Behavior | Suicidal Ideation Active
-
Emory UniversityGeorgia Institute of TechnologyCompletedSuicide, Suicidal IdeationUnited States
-
Henry M. Jackson Foundation for the Advancement...University of Pennsylvania; University of Michigan; Duke University; US Department... and other collaboratorsUnknownSuicide, Attempted | Suicidal Ideation ActiveUnited States
-
Technische Universität DresdenUnknownDepression | Suicidal Ideation/BehaviorGermany
-
International Islamic University, IslamabadRecruitingImpulsivity | Suicidal Ideation and BehaviorPakistan
-
VA Office of Research and DevelopmentCentral Texas Veterans Health Care SystemRecruitingHealth | Reintegration Difficulties | Suicidal Ideation and Behaviors | ConnectednessUnited States
-
Children's Hospital Medical Center, CincinnatiCompleted
-
Eisenhower Army Medical CenterAugusta University; The Geneva Foundation; Congressionally Directed Medical Research...CompletedSuicidal Ideation | Suicide | Suicidal Intention | Suicidal Impulses | Suicidal and Self-Injurious Behavior | Suicidal DepressionUnited States
-
Ohio State UniversityUniversity of Minnesota; Rutgers UniversityCompletedSuicidal Ideation | SuicidalUnited States
Clinical Trials on Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film
-
INSYS Therapeutics IncCompletedStudy of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy VolunteersOpiate DependenceUnited States
-
Teva Pharmaceuticals USAWithdrawn
-
Indivior Inc.Completed
-
Friends Research Institute, Inc.National Institute on Drug Abuse (NIDA); Baltimore City Health DepartmentEnrolling by invitationOpioid-use DisorderUnited States
-
Indivior Inc.Completed
-
Indivior Inc.CompletedHealthy Volunteer | Opioid-use DisorderUnited States
-
Indivior Inc.CompletedOpioid Use DisorderUnited States
-
Indivior Inc.CompletedOpioid Use Disorder | Opioid-related DisordersUnited States
-
Indivior Inc.CompletedOpioid Dependence | Opioid Related DisordersUnited States
-
Melinda SeeringCompletedAnesthesia, LocalUnited States